

2020 -- H 7068

=====
LC003315
=====

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2020

HOUSE RESOLUTION

RECOGNIZING AND HONORING THE SIXTY VOLUNTEERS WHO PARTICIPATED IN
THE BUTLER HOSPITAL MEMORY AND AGING PROGRAM'S ADUCANUMAB
CLINICAL TRIALS

Introduced By: Representatives McNamara, Ackerman, Corvese, Kislak, and Jackson

Date Introduced: January 09, 2020

Referred To: House read and passed

1 WHEREAS, Approximately 5.5 million Americans and 35 million people worldwide
2 suffer from Alzheimer's disease, a progressive neurodegenerative disorder, which is the sixth
3 leading cause of death in America; and

4 WHEREAS, The Butler Hospital Memory & Aging Program (MAP) is a worldwide
5 leader in Alzheimer's disease research with a 25 year history of excellence in clinical care,
6 training and research; and

7 WHEREAS, In order to conduct research studies and clinical trials, MAP requires
8 courageous study participants and dedicated compassionate donors as well as the support and
9 collaboration of the wider community; and

10 WHEREAS, The participation of people who were experiencing some degree of memory
11 loss, as well as those with normal memory, is necessary for research studies and clinical trials on
12 potential new treatments and drugs; and

13 WHEREAS, Sixty patients with early Alzheimer's were placed on either a placebo or the
14 drug aducanumab through a study under the guidance of Dr. Stephen Salloway at the Butler
15 Hospital Memory and Aging Program; and

16 WHEREAS, Early evidence supported that those on the medicine experienced a slower
17 decline in their memory and better preservation of day-to-day functions. Although MAP's
18 participants had seemed to be doing well, the trials were subsequently halted in March of 2019,
19 because it had appeared that the drug would not be effective; and

1 WHEREAS, In November of 2019, new and continuing data revealed that the drug was
2 working and people on aducanumab were indeed functioning better than people who got the
3 inactive medicine; and

4 WHEREAS, Over the past sixteen years, there have not been any new drugs approved by
5 the Food and Drug Administration (FDA) for Alzheimer's. If aducanumab is approved, it will be
6 the first new approval of a drug that actually targets the disease itself; and

7 WHEREAS, The success of these trials and the many medical advances is substantially
8 dependent on the registering and participation of volunteers and the support of their families and
9 the community, and they are eminently deserving of our praise and acknowledgement; now,
10 therefore be it

11 RESOLVED, That this House of Representatives of the State of Rhode Island and
12 Providence Plantations hereby recognizes, honors, and thanks those members of our community
13 who have bravely stepped forward to advance the research for a cure to Alzheimer's disease; and
14 be it further

15 RESOLVED, That the Secretary of State be and hereby is authorized and directed to
16 transmit at duly certified copy of this resolution to the Butler Hospital Memory & Aging Program
17 (MAP).

=====
LC003315
=====